Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#1191 Efficacy of Lanreotide versus Follow-up in Early-stage Duodeno-Pancreatic Neuroendocrine Tumors (NETs) Related to Multiple Endocrine Neoplasia Type 1 (MEN1): Preliminary Data

Introduction: Surgery is the only curative approach for NETs, representing the first-line therapy. As most pts with MEN1 have multiple duodeno-pancreatic NETs, cure is generally not possible, unless to adopt radical surgery. Somatostatin analogues (SSAs) represent one of the main therapeutic option in functioning well-differentiated NETs. There are no perspective studies focusing on MEN1-related NETs.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Ramundo V

Authors: Ramundo V, Marciello F, Modica R, Marotta V, Pizza G,

Keywords: Multiple Endocrine Neoplasia type 1, Lanreotide, Duodeno-pancreatic NETs.,

#901 Impact of Long-Acting Octreotide in Patients with Early-Stage MEN1-Related Duodeno-Pancreatic Neuroendocrine Tumors

Introduction: Somatostatin analogues (SSA) represent one of the main therapeutic options in patients affected by functioning well-differentiated neuroendocrine tumors (NETs). There are no studies specifically focusing on NETs associated with Multiple Endocrine Neoplasia type 1 (MEN1).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L,

Keywords: somatostatin analogues, MEN1, neuroendocrine tumors, pancreatic neuroendocrine tumor,